ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
“The second quarter was a period of sound execution and expansion at Novocure,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Our restructured commercial organization has begun driving greater penetration in key markets, the launch of Optune® in France has been a resounding success, and we are preparing to introduce our next generation arrays in more markets later this year. We believe there are many more patients who can benefit from TTFields therapy and we are determined to reach them.”
“The positive results from the LUNAR trial in non-small cell lung cancer mark the beginning of the next chapter at Novocure, as we strive to extend survival for patients diagnosed with difficult-to-treat tumors,” said William Doyle, Novocure’s Executive Chairman. “With three more phase 3 trials set to read out by the end of 2024 and a new generation of trials slated to launch, our determination and commitment are strengthened by the prospect of potentially treating many more patients across a number of new indications in the coming years.”
Financial updates for the second quarter ended June 30, 2023:
-
Total net revenues for the quarter were $126.1 million, a decrease of 11% compared to the same period in 2022. The decrease resulted primarily from $13.4 million in reduced collections from previously denied or appealed claims in the U.S.
- The United States, Germany and Japan contributed $87.0 million, $15.7 million and $7.9 million in quarterly net revenues, respectively, with our other active markets contributing $8.7 million.
- Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $6.8 million.
- Gross margin for the quarter was 73%.
- Research, development and clinical studies expenses for the quarter were $55.4 million, a decrease of 3% from the same period in 2022. This primarily reflects reduced costs associated with recently completed trials in the quarter. Total clinical trial expenses can fluctuate quarter-to-quarter dependent upon the amount of clinical research organization services delivered, clinical materials procured and number of trials actively underway. As our current phase 3 clinical trials near completion, we expect to backfill our clinical trial pipeline with new phase 2 and 3 trials.
- Sales and marketing expenses for the quarter were $58.5 million, an increase of 31% compared to the same period in 2022. This increase reflects increased investments associated with geographic expansion and pre-launch activities intended to increase awareness of TTFields therapy in anticipation of future approvals in new indications.
- General and administrative expenses for the quarter were $40.8 million, an increase of 29% compared to the same period in 2022. This reflects increased personnel and project costs to support larger patient populations, new geographic launches, supply chain expansion and information technology enhancements.
- Net loss for the quarter was $57.4 million with loss per share of $0.54.
- Adjusted EBITDA* for the quarter was $(27.2) million.
- Cash, cash equivalents and short-term investments were $940.8 million as of June 30, 2023.
Operational updates for the second quarter ended June 30, 2023:
- 1,556 prescriptions were received in the quarter, an increase of 13% compared to the same period in 2022. Prescriptions from the United States, Germany and Japan contributed 981, 204 and 92 prescriptions, respectively, with our other active markets contributing 279 prescriptions.
- As of June 30, 2023, there were 3,571 active patients on therapy. Active patients from the United States, Germany and Japan contributed 2,200, 499 and 352 active patients, respectively, with the remaining 520 active patients contributed by our other active markets.
Quarterly updates and achievements:
- In June, we presented positive results from the phase 3 LUNAR trial evaluating the use of TTFields therapy together with standard therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following platinum-failure. The LUNAR trial met its primary endpoint with a statistically significant and clinically meaningful 3-month improvement in median overall survival (OS) with TTFields therapy added to standard therapies (HR=0.74, P=0.035). Patients randomized to receive TTFields therapy together with standard therapies demonstrated median OS of 13.2 months compared to 9.9 months in patients treated with standard therapies alone. Patients randomized to receive TTFields therapy and physician’s choice immune checkpoint inhibitor (ICI) demonstrated a median OS of 18.5 months, a profound extension compared to the median OS of 10.8 months demonstrated by patients that received ICI alone (HR=0.63; P=0.03). Patients randomized to receive TTFields therapy and docetaxel had a positive survival trend with a median OS of 11.1 months vs 8.7 months. TTFields therapy was well-tolerated with no added systemic toxicities and few grade 3 (no grade 4 or 5) device-related adverse events. These data are expected to serve as the basis for a PMA submission to the FDA in the second half of 2023.
- In July, we announced that an independent data monitoring committee (DMC) reviewed the safety and efficacy data for all patients in the fully enrolled PANOVA-3 clinical trial. The interim analysis resulted in a DMC recommendation that the clinical trial proceed to final analysis. The PANOVA-3 study accrued 556 patients as of February 2023 and data will be reviewed in 2024, following an 18-month follow-up period.
- In July, the U.S. Food and Drug Administration accepted the investigation device exemption for the LUNAR-2 clinical trial, a randomized, phase 3 study testing the safety and effectiveness of TTFields therapy concomitant with pembrolizumab and platinum-based chemotherapy in patients with metastatic NSCLC. The two primary endpoints of LUNAR-2 are overall survival and progression-free survival. LUNAR-2 is designed to accrue 734 patients with a 21-month follow-up following the enrollment of the last patient.
Anticipated clinical milestones:
- Data from phase 3 INNOVATE-3 clinical trial in recurrent ovarian cancer (2H 2023)
- Top-line data from phase 3 METIS clinical trial in brain metastases (Q1 2024)
- Data from phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer (2H 2024)
Conference call details
Novocure will host a conference call and webcast to discuss second quarter 2023 financial results at 8 a.m. EDT today, Thursday, July 27, 2023. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.
The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.
*Non-GAAP Financial Measurements
We measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation ("Adjusted EBITDA"). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2023, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Consolidated Statements of Operations USD in thousands (except share and per share data) |
|||||||||||||||||||
|
Three months ended June 30, |
|
Six months ended June 30, |
|
Year ended
|
||||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2022 |
|
|
Unaudited |
|
Unaudited |
|
Audited |
||||||||||||||
Net revenues |
$ |
126,051 |
|
|
$ |
140,866 |
|
|
$ |
248,233 |
|
|
$ |
278,413 |
|
|
$ |
537,840 |
|
Cost of revenues |
|
34,018 |
|
|
|
28,503 |
|
|
|
63,632 |
|
|
|
56,230 |
|
|
|
114,867 |
|
Gross profit |
|
92,033 |
|
|
|
112,363 |
|
|
|
184,601 |
|
|
|
222,183 |
|
|
|
422,973 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
||||||||||
Research, development and clinical studies |
|
55,427 |
|
|
|
57,075 |
|
|
|
115,131 |
|
|
|
99,309 |
|
|
|
206,085 |
|
Sales and marketing |
|
58,488 |
|
|
|
44,750 |
|
|
|
109,657 |
|
|
|
82,634 |
|
|
|
173,658 |
|
General and administrative |
|
40,778 |
|
|
|
31,666 |
|
|
|
82,722 |
|
|
|
62,174 |
|
|
|
132,753 |
|
Total operating costs and expenses |
|
154,693 |
|
|
|
133,491 |
|
|
|
307,510 |
|
|
|
244,117 |
|
|
|
512,496 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Operating income (loss) |
|
(62,660 |
) |
|
|
(21,128 |
) |
|
|
(122,909 |
) |
|
|
(21,934 |
) |
|
|
(89,523 |
) |
Financial income (expenses), net |
|
8,756 |
|
|
|
(2,228 |
) |
|
|
17,925 |
|
|
|
(3,937 |
) |
|
|
7,677 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income (loss) before income taxes |
|
(53,904 |
) |
|
|
(23,356 |
) |
|
|
(104,984 |
) |
|
|
(25,871 |
) |
|
|
(81,846 |
) |
Income taxes |
|
3,514 |
|
|
|
652 |
|
|
|
5,495 |
|
|
|
2,784 |
|
|
|
10,688 |
|
Net income (loss) |
|
(57,418 |
) |
|
|
(24,008 |
) |
|
|
(110,479 |
) |
|
|
(28,655 |
) |
|
|
(92,534 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic net income (loss) per ordinary share |
$ |
(0.54 |
) |
|
$ |
(0.23 |
) |
|
$ |
(1.04 |
) |
|
$ |
(0.27 |
) |
|
$ |
(0.88 |
) |
Weighted average number of ordinary shares used in computing basic net income (loss) per share |
|
106,289,073 |
|
|
|
104,627,789 |
|
|
|
105,979,791 |
|
|
|
104,408,164 |
|
|
|
104,660,476 |
|
Diluted net income (loss) per ordinary share |
$ |
(0.54 |
) |
|
$ |
(0.23 |
) |
|
$ |
(1.04 |
) |
|
$ |
(0.27 |
) |
|
$ |
(0.88 |
) |
Weighted average number of ordinary shares used in computing diluted net income (loss) per share |
|
106,289,073 |
|
|
|
104,627,789 |
|
|
|
105,979,791 |
|
|
|
104,408,164 |
|
|
|
104,660,476 |
|
Consolidated Balance Sheets USD in thousands (except share data) |
|||||
|
June 30,
|
|
December 31,
|
||
|
Unaudited |
|
Audited |
||
ASSETS |
|
|
|
||
CURRENT ASSETS: |
|
|
|
||
Cash and cash equivalents |
$ |
156,978 |
|
$ |
115,326 |
Short-term investments |
|
783,837 |
|
|
854,099 |
Restricted cash |
|
516 |
|
|
508 |
Trade receivables, net |
|
70,988 |
|
|
86,261 |
Receivables and prepaid expenses |
|
20,148 |
|
|
25,959 |
Inventories |
|
33,023 |
|
|
29,376 |
Total current assets |
|
1,065,490 |
|
|
1,111,529 |
LONG-TERM ASSETS: |
|
|
|
||
Property and equipment, net |
|
41,156 |
|
|
32,678 |
Field equipment, net |
|
11,519 |
|
|
12,684 |
Right-of-use assets |
|
26,278 |
|
|
23,596 |
Other long-term assets |
|
14,572 |
|
|
11,161 |
Total long-term assets |
|
93,525 |
|
|
80,119 |
TOTAL ASSETS |
$ |
1,159,015 |
|
$ |
1,191,648 |
|
|
|
|
||
Consolidated Balance Sheets USD in thousands (except share data) |
|||||||
|
June 30,
|
|
December 31,
|
||||
|
Unaudited |
|
Audited |
||||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
||||
CURRENT LIABILITIES: |
|
|
|
||||
Trade payables |
$ |
82,536 |
|
|
$ |
85,197 |
|
Other payables, lease liabilities and accrued expenses |
|
67,551 |
|
|
|
73,580 |
|
Total current liabilities |
|
150,087 |
|
|
|
158,777 |
|
LONG-TERM LIABILITIES: |
|
|
|
||||
Long-term debt, net |
|
567,150 |
|
|
|
565,509 |
|
Deferred revenues |
|
807 |
|
|
|
2,878 |
|
Long-term leases |
|
20,329 |
|
|
|
18,762 |
|
Employee benefit liabilities |
|
4,840 |
|
|
|
4,404 |
|
Other long-term liabilities |
|
119 |
|
|
|
148 |
|
Total long-term liabilities |
|
593,245 |
|
|
|
591,701 |
|
TOTAL LIABILITIES |
|
743,332 |
|
|
|
750,478 |
|
|
|
|
|
||||
COMMITMENTS AND CONTINGENCIES |
|
|
|
||||
|
|
|
|
||||
SHAREHOLDERS' EQUITY: |
|
|
|
||||
Share capital - |
|
|
|
||||
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 106,605,331 shares and 105,049,411 shares at June 30, 2023 (unaudited) and December 31, 2022, respectively |
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
1,306,603 |
|
|
|
1,222,063 |
|
Accumulated other comprehensive income (loss) |
|
(1,981 |
) |
|
|
(2,433 |
) |
Retained earnings (accumulated deficit) |
|
(888,939 |
) |
|
|
(778,460 |
) |
TOTAL SHAREHOLDERS' EQUITY |
|
415,683 |
|
|
|
441,170 |
|
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
$ |
1,159,015 |
|
|
$ |
1,191,648 |
|
Non-U.S. GAAP financial measures reconciliation USD in thousands |
|||||||||||||||||||||
|
Three months ended June 30, |
|
Six months ended June 30, |
||||||||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
%Change |
|
|
2023 |
|
|
|
2022 |
|
|
%Change |
||
Net income (loss) |
$ |
(57,418 |
) |
|
$ |
(24,008 |
) |
|
139 |
% |
|
$ |
(110,479 |
) |
|
$ |
(28,655 |
) |
|
286 |
% |
Add: Income tax |
|
3,514 |
|
|
|
652 |
|
|
439 |
% |
|
|
5,495 |
|
|
|
2,784 |
|
|
97 |
% |
Add: Financial expenses (income), net |
|
(8,756 |
) |
|
|
2,228 |
|
|
(493 |
)% |
|
|
(17,925 |
) |
|
|
3,937 |
|
|
(555 |
)% |
Add: Depreciation and amortization |
|
2,721 |
|
|
|
2,654 |
|
|
3 |
% |
|
|
5,443 |
|
|
|
5,264 |
|
|
3 |
% |
EBITDA |
$ |
(59,939 |
) |
|
$ |
(18,474 |
) |
|
224 |
% |
|
$ |
(117,466 |
) |
|
$ |
(16,670 |
) |
|
605 |
% |
Add: Share-based compensation |
|
32,740 |
|
|
|
25,823 |
|
|
27 |
% |
|
|
71,824 |
|
|
|
50,868 |
|
|
41 |
% |
Adjusted EBITDA |
$ |
(27,199 |
) |
|
$ |
7,349 |
|
|
(470 |
)% |
|
$ |
(45,642 |
) |
|
$ |
34,198 |
|
|
(233 |
)% |
